DiamiR Biosciences Corp. (DIMR)

DiamiR Biosciences Income Statement

Financials in millions USD. Fiscal year is June - May.

Year Ending	TTM	May 31, 2023	May 31, 2022
Revenue	1.32	1.13	1.44
Revenue Growth (YoY)	-	-21.71%	-
Gross Profit	1.32	1.13	1.44
Selling, General & Admin	-	0.92	0.44
Research & Development	-	1.36	1.16
Operating Expenses	-	2.29	1.6
Operating Income	-0.5	-1.16	-0.16
Interest Expense / Income	0.04	0.11	0.17
Pretax Income	-0.55	-1.27	-0.32
Income Tax	0.09	0.05	-
Net Income	-0.63	-1.32	-0.32
Free Cash Flow	-0.24	-0.21	0.12
Gross Margin	100.00%	100.00%	100.00%
Operating Margin	-37.88%	-102.63%	-10.78%
Profit Margin	-47.98%	-116.88%	-22.29%
Free Cash Flow Margin	-18.34%	-18.38%	8.36%
EBITDA	-0.46	-1.07	-0.03
EBITDA Margin	-34.63%	-94.68%	-2.19%
Depreciation & Amortization	0.04	0.09	0.12
EBIT	-0.5	-1.16	-0.16
EBIT Margin	-37.88%	-102.63%	-10.78%

Source: IPO financials are sourced from S-1 and S-1/A filings submitted to the Securities and Exchange Commission (SEC).